This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: March 21, 2006
Last updated: December 2, 2016
Last verified: September 2016
The aim of the study is to compare the effect of ciclesonide on quality of life, pulmonary function and time to first exacerbation in patients with moderate persistent asthma. Ciclesonide will be administered once daily in the evening at two dose levels. The study duration consists of a baseline period (2 weeks) and a treatment period (8 weeks).

Condition Intervention Phase
Asthma Drug: Ciclesonide Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Pilot Study on the Impact of Two Different Doses of Ciclesonide (160 mcg/Day and 320 mcg/Day) Administered in the Evening on Quality of Life in Patients With Moderate Persistent Asthma.

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • differences in Quality of Life from AQLQ(S) (T end versus T0) [ Time Frame: 8 weeks ]
  • time to first exacerbation [ Time Frame: 8 weeks ]
  • differences in FEV1 and FVC from spirometry (T end vs T0). [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • percentage of days on which patients perceived asthma control [ Time Frame: 8 weeks ]
  • percentage of asthma symptoms free days [ Time Frame: 8 weeks ]
  • percentage of rescue medication-free days [ Time Frame: 8 weeks ]
  • percentage of nocturnal awakening-free days [ Time Frame: 8 weeks ]
  • asthma symptom score (daytime score, nighttime score, total score) [ Time Frame: 8 weeks ]
  • use of rescue medication [ Time Frame: 8 weeks ]
  • PEF from spirometry [ Time Frame: 8 weeks ]
  • morning and evening PEF from diary [ Time Frame: 8 weeks ]
  • diurnal PEF fluctuation. [ Time Frame: 8 weeks ]

Enrollment: 101
Study Start Date: February 2006
Study Completion Date: February 2008
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Ciclesonide 160µg
Drug: Ciclesonide
Effect of Ciclesonide on Quality of Life
Active Comparator: 2
Ciclesonide 320µg
Drug: Ciclesonide
Effect of Ciclesonide on Quality of Life


Ages Eligible for Study:   21 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • Written informed consent
  • Good health with the exception of asthma
  • Clinical diagnosis of moderate persistent asthma during the last 6 months prior to visit B0
  • Pre-treatment with inhaled corticosteroids dose equivalent to 250 - 500 mcg BDP / day at stable dosing during the last 4 weeks prior to visit B0, concomitant or not to short-acting beta2-agonists treatment as rescue medication
  • FEV1 ≥ 70% and ≤ 90% predicted measured at least 4 h after the last use of rescue medication at visit B0
  • Reversibility ≥ 12% and ≥ 200 mL in B0, B0 or T0, after inhalation of 400 mcg of salbutamol
  • Patients compliant to recommended pre-treatment

Main Exclusion Criteria:

  • Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids
  • Chronic obstructive pulmonary disease (COPD)
  • Hospitalization within previous four weeks from baseline
  • Hospitalization due to asthma within the last twelve months
  • Asthma exacerbation within two months previous to baseline
  • History of almost fatal asthma at any moment
  • Pregnancy, breast feeding, intention to become pregnant during the course of the study or lack of safe contraception in pre-menopausal women
  • Exacerbation of asthma within 2 months prior to entry into the baseline period
  • Use of systemic steroids up to 2 months (injectable depot steroids 6 months) before entry into the baseline period, or more than 3 times during the last 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00305461

Altana Pharma/Nycomed
Buenos Aires, Argentina, B1902CSK
Altana Pharma/Nycomed
Buenos Aires, Argentina, B7540GHQ
Altana Pharma/Nycomed
Buenos Aires, Argentina, B8000AAT
Altana Pharma/Nycomed
Cap. Fed., Argentina, C1117ABE
Altana Pharma/Nycomed
Cap. Fed., Argentina, C1121ABE
Altana Pharma/Nycomed
Cap. Fed., Argentina, C1221ADC
Altana Pharma/Nycomed
Cap. Fed., Argentina, C1427ARN
Altana Pharma/Nycomed
Cordoba, Argentina, X5000BFB
Altana Pharma/Nycomed
Cordoba, Argentina, X5016KEH
Altana Pharma/Nycomed
Mendoza, Argentina, M5500CCG
Altana Pharma/Nycomed
Santa Fe, Argentina, S2000DSV
Altana Pharma/Nycomed
Tucuman, Argentina, T4146DAL
Sponsors and Collaborators
Study Director: AstraZeneca AstraZeneca AstraZeneca
  More Information

Additional Information:
Responsible Party: AstraZeneca Identifier: NCT00305461     History of Changes
Other Study ID Numbers: BY9010/AR-101
Study First Received: March 21, 2006
Last Updated: December 2, 2016

Keywords provided by AstraZeneca:
Quality of Life

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Allergic Agents processed this record on July 27, 2017